4-Amino-1,2,4-triazole (AMT) is a heterocyclic organic compound with the formula C2H4N4. It is a white solid that is soluble in water. AMT is a versatile building block in organic synthesis and has a wide range of applications, including:
- **Synthesis:** AMT can be synthesized from various starting materials, including formamide, hydrazine, and dicyandiamide. The most common synthetic route involves the condensation reaction of formamide and hydrazine.
- **Effects:** AMT exhibits diverse biological activities, including antitumor, antimicrobial, and anti-inflammatory properties. It is a potent inhibitor of the enzyme carbonic anhydrase, which plays a role in various physiological processes.
- **Importance:** AMT has found applications in various fields, including:
- **Agriculture:** AMT is used as a herbicide to control broadleaf weeds and grasses.
- **Pharmaceuticals:** AMT derivatives have been investigated as potential anticancer agents and for treating other diseases.
- **Materials Science:** AMT is used as a monomer in the synthesis of polymers and other materials.
- **Why it is studied:** The versatility of AMT as a synthetic building block, its diverse biological activities, and its potential applications in various fields have led to extensive research on its chemistry, synthesis, and applications.
'
4-amino-1,2,4-triazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11432 |
| CHEMBL ID | 1868166 |
| MeSH ID | M0527751 |
| Synonym |
|---|
| o57y04816h , |
| 5-26-01-00095 (beilstein handbook reference) |
| unii-o57y04816h |
| 4h-[1,2,4]triazol-4-yl-amine |
| nsc-3263 |
| 1-amino-1h-1,4-triazole |
| 4h-1,4-triazole, 4-amino- |
| nsc3263 |
| 4-amino-1,4(4h)-triazole |
| 4h-1,4-triazol-4-amine |
| 584-13-4 |
| 1-amino-1,4-triazole |
| nsc7242 |
| 4-amino-4h-1,4-triazole |
| 4-amino-1,4-triazole |
| nsc-7242 |
| 4h-1,2,4-triazole, 4-amino- |
| 1,2,4-triazol-4-amine |
| 4-amino-1,2,4-triazole |
| NCGC00090928-01 |
| 4-amino-4h-1,2,4-triazole, reagentplus(r), 99% |
| 1-amino-1h-1,3,4-triazole |
| nsc 3263 |
| nsc 7242 |
| 4h-1,2,4-triazol-4-ylamine |
| 4-amino-1,2,4(4h)-triazole |
| einecs 209-533-5 |
| 4-amino-4h-1,2,4-triazole |
| brn 0107563 |
| 1-amino-1,3,4-triazole |
| ai3-23640 |
| 4h-1,2,4-triazol-4-amine |
| STK396235 |
| A1137 |
| F1918-0006 |
| fmcupjktgnbgec-uhfffaoysa- |
| inchi=1/c2h4n4/c3-6-1-4-5-2-6/h1-2h,3h2 |
| AKOS000119326 |
| A831867 |
| NCGC00090928-02 |
| NCGC00090928-03 |
| tox21_300197 |
| tox21_201893 |
| NCGC00259442-01 |
| NCGC00254186-01 |
| dtxcid7013058 |
| dtxsid9033058 , |
| cas-584-13-4 |
| FT-0617424 |
| AM20100424 |
| 4h-1,2,4-triazole-4-amine |
| 4-amino[1,2,4]triazole |
| [1,2,4]triazol-4-ylamine |
| 1,2,4-triazol-4-ylamine |
| W-105389 |
| CHEMBL1868166 |
| STR01763 |
| CS-W019307 |
| PS-9366 |
| mfcd00003099 |
| 4-amino-4h-1,2,4-triazole, vetec(tm) reagent grade, 98% |
| SY001769 |
| 4-amino-[1,2,4]triazole |
| AC7809 |
| Q27285357 |
| EN300-19043 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.3390 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 28.1838 | 0.0010 | 19.4141 | 70.9645 | AID588536 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 33.4915 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 53.0804 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleoplasm | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nuclear body | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| chromatin | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (44.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||